Skip to main content

Advertisement

SpringerLink
Log in

Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Swerdlow SH, Webber SA, Chadburn A, Ferry JA (2017) Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 453–462

    Google Scholar 

  2. Cheung CY, Tam S, Lam CW, Lie AK, Kwong YL (2015) Allogeneic haematopoietic stem cell transplantation for erythropoietic protoporphyria: a cautionary note. Blood Cells Mol Dis 54(3):266–267. https://doi.org/10.1016/j.bcmd.2014.11.009

    Article  PubMed  Google Scholar 

  3. Kwong YL, Pang AW, Leung AY, Chim CS, Tse E (2014) Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia 28(4):865–870. https://doi.org/10.1038/leu.2013.212

    Article  CAS  PubMed  Google Scholar 

  4. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34(23):2690–2697. https://doi.org/10.1200/JCO.2016.66.4482

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Liu WR, Shipp MA (2017) Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 130(21):2265–2270. https://doi.org/10.1182/blood-2017-06-781989

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611–1618. https://doi.org/10.1158/1078-0432.CCR-11-1942

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A (2017) Moskowitz CH; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL (2017) Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol 96(4):647–651. https://doi.org/10.1007/s00277-017-2931-z

    Article  CAS  PubMed  Google Scholar 

  9. Hwang YY, Khong PL, Kwong YL (2017) Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol 96(7):1219–1220. https://doi.org/10.1007/s00277-017-3007-9

    Article  PubMed  Google Scholar 

  10. Kwong YL (2016) Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol 95(7):1191–1192. https://doi.org/10.1007/s00277-016-2651-9

    Article  PubMed  Google Scholar 

  11. Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471–2478. https://doi.org/10.1182/blood-2016-11-749556

    Article  CAS  Google Scholar 

  12. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A, Parr NNC, Baig Z, Sagar F, Ali Z, McBride A, Anwer F (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94–99. https://doi.org/10.1016/j.bbmt.2018.08.028

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Pok Fu Lam, Hong Kong

    Joycelyn P. Y. Sim & Yok-Lam Kwong

  2. Department of Pathology, Queen Mary Hospital, Pok Fu Lam, Hong Kong

    Rex Au-Yeung

Authors
  1. Joycelyn P. Y. Sim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rex Au-Yeung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yok-Lam Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.P.Y. Sim: treated the patient, wrote and approved the manuscript

Rex Au-Yeung: performed the histopathological examination, wrote and approved the manuscript

Y.L. Kwong: treated the patient, wrote and approved the manuscript

Corresponding author

Correspondence to Yok-Lam Kwong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of informed consent

Patient gave informed consent to treatment.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sim, J.P.Y., Au-Yeung, R. & Kwong, YL. Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma. Ann Hematol 99, 385–388 (2020). https://doi.org/10.1007/s00277-019-03856-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03856-y

Search

Navigation